Citadel Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.66M | Buy |
9,600
+4,200
| +78% | +$779K | ﹤0.01% | 6507 |
|
|
2025
Q4 | $1.08M | Sell |
5,400
-9,000
| -63% | -$1.63M | ﹤0.01% | 7225 |
|
|
2025
Q3 | $2.25M | Sell |
14,400
-28,000
| -66% | -$4.45M | ﹤0.01% | 5838 |
|
|
2025
Q2 | $6.43M | Sell |
42,400
-3,300
| -7% | -$440K | ﹤0.01% | 3693 |
|
|
2025
Q1 | $6.88M | Sell |
45,700
-1,700
| -4% | -$285K | ﹤0.01% | 3390 |
|
|
2024
Q4 | $8.75M | Buy |
47,400
+8,400
| +22% | +$1.62M | ﹤0.01% | 3151 |
|
|
2024
Q3 | $7.68M | Sell |
39,000
-15,900
| -29% | -$3.3M | ﹤0.01% | 3297 |
|
|
2024
Q2 | $11.3M | Sell |
54,900
-15,200
| -22% | -$3.44M | ﹤0.01% | 2621 |
|
|
2024
Q1 | $19M | Buy |
70,100
+24,600
| +54% | +$5.87M | ﹤0.01% | 2118 |
|
|
2023
Q4 | $10.8M | Buy |
45,500
+21,600
| +90% | +$4.25M | ﹤0.01% | 2742 |
|
|
2023
Q3 | $4.68M | Buy |
23,900
+18,400
| +335% | +$3.78M | ﹤0.01% | 3756 |
|
|
2023
Q2 | $1.16M | Sell |
5,500
-1,900
| -26% | -$378K | ﹤0.01% | 6160 |
|
|
2023
Q1 | $1.49M | Sell |
7,400
-18,900
| -72% | -$4.28M | ﹤0.01% | 5920 |
|
|
2022
Q4 | $5.73M | Buy |
26,300
+16,100
| +158% | +$3.52M | ﹤0.01% | 3630 |
|
|
2022
Q3 | $2.01M | Sell |
10,200
-11,500
| -53% | -$2.48M | ﹤0.01% | 5577 |
|
|
2022
Q2 | $4.64M | Sell |
21,700
-14,600
| -40% | -$3.57M | ﹤0.01% | 3941 |
|
|
2022
Q1 | $10.3M | Buy |
36,300
+9,700
| +36% | +$2.99M | ﹤0.01% | 2899 |
|
|
2021
Q4 | $10M | Sell |
26,600
-10,300
| -28% | -$4M | ﹤0.01% | 3068 |
|
|
2021
Q3 | $15.2M | Buy |
36,900
+24,000
| +186% | +$9.97M | ﹤0.01% | 2411 |
|
|
2021
Q2 | $4.77M | Sell |
12,900
-8,700
| -40% | -$2.91M | ﹤0.01% | 4543 |
|
|
2021
Q1 | $6.26M | Buy |
21,600
+14,000
| +184% | +$3.89M | ﹤0.01% | 3797 |
|
|
2020
Q4 | $1.9M | Sell |
7,600
-1,500
| -16% | -$357K | ﹤0.01% | 5447 |
|
|
2020
Q3 | $2.06M | Sell |
9,100
-2,200
| -19% | -$457K | ﹤0.01% | 4654 |
|
|
2020
Q2 | $1.97M | Sell |
11,300
-6,200
| -35% | -$989K | ﹤0.01% | 4612 |
|
|
2020
Q1 | $2.21M | Buy |
17,500
+9,600
| +122% | +$1.44M | ﹤0.01% | 3977 |
|
|
2019
Q4 | $1.21M | Buy |
7,900
+1,400
| +22% | +$194K | ﹤0.01% | 5261 |
|
|
2019
Q3 | $860K | Sell |
6,500
-3,300
| -34% | -$442K | ﹤0.01% | 5848 |
|
|
2019
Q2 | $1.39M | Hold |
9,800
| – | – | ﹤0.01% | 5143 |
|
|
2019
Q1 | $1.42M | Sell |
9,800
-6,600
| -40% | -$867K | ﹤0.01% | 4992 |
|
|
2018
Q4 | $1.86M | Buy |
16,400
+5,100
| +45% | +$639K | ﹤0.01% | 4260 |
|
|
2018
Q3 | $1.52M | Buy |
11,300
+7,900
| +232% | +$975K | ﹤0.01% | 4855 |
|
|
2018
Q2 | $382K | Sell |
3,400
-1,700
| -33% | -$184K | ﹤0.01% | 6810 |
|
|
2018
Q1 | $544K | Buy |
5,100
+2,700
| +113% | +$291K | ﹤0.01% | 5746 |
|
|
2017
Q4 | $263K | Sell |
2,400
-7,800
| -76% | -$849K | ﹤0.01% | 6669 |
|
|
2017
Q3 | $1.1M | Sell |
10,200
-2,400
| -19% | -$247K | ﹤0.01% | 4179 |
|
|
2017
Q2 | $1.27M | Buy |
12,600
+3,200
| +34% | +$295K | ﹤0.01% | 3752 |
|
|
2017
Q1 | $846K | Buy |
+9,400
| New | +$798K | ﹤0.01% | 4245 |
|
|
2016
Q3 | – | Sell |
-3,300
| Closed | -$272K | – | 7289 |
|
|
2016
Q2 | $272K | Buy |
3,300
+400
| +14% | +$32.9K | ﹤0.01% | 5366 |
|
|
2016
Q1 | $220K | Sell |
2,900
-5,100
| -64% | -$378K | ﹤0.01% | 5519 |
|
|
2015
Q4 | $643K | Sell |
8,000
-6,200
| -44% | -$447K | ﹤0.01% | 4148 |
|
|
2015
Q3 | $902K | Buy |
14,200
+13,100
| +1,191% | +$941K | ﹤0.01% | 3954 |
|
|
2015
Q2 | $77K | Hold |
1,100
| – | – | ﹤0.01% | 7330 |
|
|
2015
Q1 | $87K | Hold |
1,100
| – | – | ﹤0.01% | 6951 |
|
|
2014
Q4 | $70K | Sell |
1,100
-400
| -27% | -$25.1K | ﹤0.01% | 6946 |
|
|
2014
Q3 | $90K | Sell |
1,500
-53,300
| -97% | -$3.05M | ﹤0.01% | 6502 |
|
|
2014
Q2 | $2.93M | Buy |
54,800
+45,600
| +496% | +$2.5M | ﹤0.01% | 2362 |
|
|
2014
Q1 | $555K | Buy |
9,200
+7,900
| +608% | +$460K | ﹤0.01% | 4210 |
|
|
2013
Q4 | $69K | Sell |
1,300
-900
| -41% | -$45.2K | ﹤0.01% | 5864 |
|
|
2013
Q3 | $102K | Sell |
2,200
-500
| -19% | -$22.9K | ﹤0.01% | 5334 |
|
|
2013
Q2 | $111K | Buy |
+2,700
| New | +$116K | ﹤0.01% | 5136 |
|
Other funds holding CRL
VCM
VPM
Citadel Advisors's CRL Position: Q1 2026 in Review
Citadel Advisors increased its Charles River Laboratories (CRL) stake by 190% in Q1 2026, buying an estimated $147M and bringing the position to 1,212,152 shares worth $209M. The position accounts for 0.03% of the portfolio, ranked #440.
Citadel Advisors first reported a position in CRL in Q2 2013 and has held it in 51 quarters since. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- Citadel Advisors held 1,212,152 shares of Charles River Laboratories worth $209M as of Q1 2026.
- Citadel Advisors bought 794,636 Charles River Laboratories shares in Q1 2026, an estimated $147M.
- Charles River Laboratories made up 0.03% of Citadel Advisors's portfolio in Q1 2026, its #440 holding.
- Citadel Advisors first reported a position in Charles River Laboratories in Q2 2013 and has held it in 51 quarters since.
- 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.